270. Chronic recurrent multifocal osteomyelitis Disease details / Clinical trials / Drug dev / DR info
Clinical trial : 1 / Drugs : 10 - (DrugBank : 9) / Drug target genes : 6 - Drug target pathways : 73
Drugs and their primary sponsors and trial info
Adalimumab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Certolizumab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Etanercept
Seattle Children's Hospital
2018 - NCT04725422 United States;
Golimumab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Infliximab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Leflunomide
Seattle Children's Hospital
2018 - NCT04725422 United States;
Methotrexate
Seattle Children's Hospital
2018 - NCT04725422 United States;
Pamidronate
Seattle Children's Hospital
2018 - NCT04725422 United States;
Sulfasalazine
Seattle Children's Hospital
2018 - NCT04725422 United States;
Zoledronic acid
Seattle Children's Hospital
2018 - NCT04725422 United States;
Seattle Children's Hospital
2018 - NCT04725422 United States;
Certolizumab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Etanercept
Seattle Children's Hospital
2018 - NCT04725422 United States;
Golimumab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Infliximab
Seattle Children's Hospital
2018 - NCT04725422 United States;
Leflunomide
Seattle Children's Hospital
2018 - NCT04725422 United States;
Methotrexate
Seattle Children's Hospital
2018 - NCT04725422 United States;
Pamidronate
Seattle Children's Hospital
2018 - NCT04725422 United States;
Sulfasalazine
Seattle Children's Hospital
2018 - NCT04725422 United States;
Zoledronic acid
Seattle Children's Hospital
2018 - NCT04725422 United States;